This phenomenon is associated with the overexpression of key enzymes, such as HMGCR, and transcription factors, including SREBP, involved in the cholesterol biosynthesis pathway (62, 64)
The FDA has not approved BPC-157 for any indication, and compounded BPC-157 falls under the agency's oversight of bulk drug substances used in compounding [9]
Drug therapy usually is considered as an option only if non-pharmacologic interventions (altered diet and exercise) have failed to lower plasma lipids
Learn more and connect at MyHeartDiseaseTeam.com
(FDA oversight is basically an established safety standard regarding how a product is manufactured in a compounding pharmacy facility, less so about its performance or safety.) A reversal would not automatically open the floodgates, but it would be a significant change, notes Hajduczok